Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.54 |
| ▸ | PGR | P06401 | 7/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.34 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13372776 | 0.84 | AR (0.53) | ARPGRNR3C2CYP19A1SHBG | |
| SCHEMBL2929841 | 0.82 | AR (0.57) | ARPGRNR3C2CYP19A1SLC22A1 | |
| SCHEMBL13217275 | 0.82 | AR (0.57) | ARPGRNR3C2CYP19A1SLC22A1 | |
| SCHEMBL13809834 | 0.78 | AR (0.58) | ARPGRNR3C2CYP19A1 | |
| SCHEMBL1656805 | 0.78 | AR (0.58) | ARPGRNR3C2CYP19A1 | |
| SCHEMBL12638972 | 0.76 | AR (0.56) | ARPGRNR3C2CYP19A1SLC22A1 | |
| SCHEMBL4220631 | 0.76 | CYP19A1 (0.60) | ARPGRNR3C2CYP19A1SLC22A1 | |
| SCHEMBL7703808 | 0.75 | SHBG (0.59) | ARPGRNR3C2CYP19A1SLC22A1 | |
| SCHEMBL2832958 | 0.75 | SHBG (0.59) | ARPGRNR3C2CYP19A1SLC22A1 | |
| SCHEMBL13474816 | 0.75 | AR (0.55) | ARPGRNR3C2CYP19A1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207150-B2 | 17β-cyano-19-nor-androst-4-ene derivative, its use and medicaments comprising the derivative | Bayer Pharma AG (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20090048217-A1 | 17Beta-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048217-A1 | 17Beta-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B11, HSD17B7, NR5A1 | AR 109/4885PGR 87/4885NR3C2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.